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Abstract
Purpose Phase Ib study evaluating the effect of apalutamide, at therapeutic exposure, on ventricular repolarization by apply-
ing time-matched pharmacokinetics and electrocardiography (ECG) in patients with castration-resistant prostate cancer. 
Safety of daily apalutamide was also assessed.
Methods Patients received 240 mg oral apalutamide daily. Time-matched ECGs were collected via continuous 12-lead 
Holter recording before apalutamide (Day − 1) and on Days 1 and 57 (Cycle 3 Day 1). Pharmacokinetics of apalutamide 
were assessed on Days 1 and 57 at matched time points of ECG collection. QT interval was corrected for heart rate using 
Fridericia correction (QTcF). The primary endpoint was the maximum mean change in QTcF (ΔQTcF) from baseline to 
Cycle 3 Day 1 (steady state). Secondary endpoints were the effect of apalutamide on other ECG parameters, pharmacokinetics 
of apalutamide and its active metabolite, relationship between plasma concentrations of apalutamide and QTcF, and safety.
Results Forty-five men were enrolled; 82% received treatment for ≥ 3 months. At steady state, the maximum ΔQTcF was 
12.4 ms and the upper bound of its associated 90% CI was 16.0 ms. No clinically meaningful effects of apalutamide were 
reported for heart rate or other ECG parameters. A concentration-dependent increase in QTcF was observed for apalutamide. 
Most adverse events (AEs) (73%) were grade 1–2 in severity. No patients discontinued due to QTc prolongation or AEs.
Conclusion The effect of apalutamide on QTc prolongation was modest and does not produce a clinically meaningful effect 
on ventricular repolarization. The AE profile was consistent with other studies of apalutamide.
Keywords Apalutamide · Castration-resistant prostate cancer · Ventricular repolarization · QT interval · Pharmacokinetics
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Introduction
Prostate cancer is the second most common cancer in men 
worldwide, accounting for 15% of cancers diagnosed in 
men [1]. Metastatic castration-resistant prostate cancer 
(mCRPC) is associated with progressive morbidities, 
including skeletal-related events [2]. Because prostate 
cancer cells depend on the androgen receptor (AR) for 
survival and growth, treatment for recurrent or primary 
metastatic prostate cancer targets this receptor axis [3]. 
Despite initial therapies that target the AR, many patients 
progress to CRPC [3]. Apalutamide is an orally adminis-
tered next-generation AR inhibitor currently approved in 
the United States for patients with nonmetastatic CRPC 
(nmCRPC) [4]. It directly binds the ligand-binding domain 
of the AR, inhibits AR nuclear translocation and DNA 
binding, and impedes AR-mediated transcription [5].
The efficacy and safety of apalutamide were demon-
strated in patients with prostate cancer in the SPARTAN 
study, a randomized, double-blind, placebo-controlled, 
multicenter trial that evaluated apalutamide treatment 
in 1207 patients with high-risk nmCRPC [6]. This study 
was the first to demonstrate a significantly longer median 
metastasis-free survival (MFS; 2 years over placebo) in 
apalutamide-treated patients compared with placebo-
treated patients, with consistent benefit for apalutamide 
across all secondary endpoints, including time to symp-
tomatic progression [6]. Minimal cardiac adverse events 
(AEs) were observed; atrial fibrillation was cited as the 
primary cardiac-associated AE reason for dose interrup-
tion and occurred in 0.7 and 0.5% of patients in the apalu-
tamide and placebo arms, respectively. Based on these 
data, apalutamide was approved in February 2018 by the 
US Food and Drug Administration (FDA) for the treatment 
of men with nmCRPC [4].
Apalutamide pharmacokinetics (PK) has been well 
characterized in clinical studies. Apalutamide is rapidly 
absorbed, with a median time to maximum observed 
plasma concentration (Cmax) of 2–3 h after oral adminis-
tration [7]. Additionally, PK was approximately propor-
tional across dose levels, with a mean effective half-life 
of approximately 3 days after multiple doses (Data on file, 
Janssen). Steady state exposure was achieved following 
4 weeks of continuous, daily apalutamide administration 
[4, 7]. For N-desmethyl apalutamide, a minimal peak to 
trough fluctuation ratio in plasma at steady state (≈ 1.3) 
was observed. Time to reach Cmax (tmax) for N-desmethyl 
apalutamide at steady state was variable and typically 
occurred at around 1 or 24 h post dose (Data on file, 
Janssen).
The preclinical cardiovascular safety of apalutamide 
and its active metabolite N-desmethyl apalutamide has 
been assessed in in vitro and in vivo studies (Data on file, 
Janssen). Both apalutamide and N-desmethyl apalutamide 
inhibited human ether-à-go-go-related (hERG) gene cur-
rent, with half maximal inhibitory concentration  (IC50) 
values of 6.17 and 4.56 µM, respectively, representing 
a safety margin of at least seven relative to the antici-
pated Cmax for unbound apalutamide and N-desmethyl 
apalutamide in patients at the clinical dose of 240 mg/day 
(Data on file, Janssen). No relevant effect was produced 
(no prolongation in action potential duration; no effect on 
resting membrane potential) in isolated canine Purkinje 
fibers with up to 30 µM of apalutamide or N-desmethyl 
apalutamide (Data on file, Janssen). Preclinical in vitro 
receptor binding assay testing did not reveal an effect of 
apalutamide on  Na+ or  Ca2+ channels (Data on file, Jans-
sen). No in vivo treatment-related cardiovascular effects 
(blood pressure, heart rate, body temperature, ECG lead 
II intervals, PR, QRS, QT, QTc, or ECG waveform mor-
phology) were noted in a single-dose telemetry study in 
conscious dogs up to 40 mg/kg or after repeated dosing in 
good laboratory practice toxicology studies in dogs up to 
10 mg/kg/day with exposures in the range of the clinical 
exposure for apalutamide and its metabolite N-desmethyl 
apalutamide (Data on file, Janssen). Overall preclinical 
cardiovascular safety assessment of apalutamide was not 
indicative of an increased risk for QTc prolongation in 
clinical use (Data on file, Janssen).
The effect of apalutamide on ventricular repolarization 
was previously evaluated as part of a phase I/II study [7] 
that included time-matched triplicate 12-lead electrocardio-
grams (ECGs) collected at baseline and at steady state in 12 
patients with CRPC. The data showed no significant effect 
from apalutamide on ECG parameters, and there was no 
conclusive evidence for an increase in Fridericia corrected 
QT interval (QTcF) (Data on file, Janssen).
Androgen deprivation therapy (ADT) can increase car-
diovascular risk because of its adverse effect on risk factors 
for cardiovascular disease [8, 9]. Combination treatment 
with bicalutamide plus LHRH agonist therapy and 150-mg 
bicalutamide monotherapy may lead to QTc prolongation 
[10–12]. In AFFIRM, a randomized phase III study, the 
effect of enzalutamide (160 mg/day) on QTcF was assessed 
at steady state in 800 patients with CRPC [13]. No clinically 
meaningful changes were observed between the mean QTcF 
interval change from baseline in patients treated with enzalu-
tamide versus those treated with placebo [13]. A recent post 
hoc analysis of the TERRAIN study suggests a higher risk 
for atrial fibrillation in patients with mCRPC taking enzalu-
tamide (160 mg/day) versus bicalutamide (50 mg/day) [14].
Because drug-induced QT interval prolongation has been 
one of the most common causes of drug withdrawals or 
restrictions of already marketed drugs [15, 16], a thorough 
premarketing assessment of a drug’s potential to cause ECG 
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change or generate life-threatening arrhythmias is a regula-
tory requirement detailed in the International Conference on 
Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use—Harmonised Tripartite 
Guideline E14 (ICH E14) [17]. Therefore, the current study 
evaluated the effect of therapeutic doses of apalutamide 
(240 mg) and its active metabolite, N-desmethyl apaluta-
mide, on ventricular repolarization in patients with CRPC.
In accordance with the ICH E14 guideline, a thorough QT 
(TQT) study ideally has a four-way crossover design, includ-
ing a therapeutic dose, a supratherapeutic dose, a placebo, 
and a positive control. In light of the absence of a preclinical 
QT signal and no conclusive evidence for QTc prolonga-
tion in a previous phase I/II study, combined with the need 
for ≥ 8 weeks of dosing with apalutamide to reach steady 
state conditions, providing 8 weeks of placebo treatment in 
a cancer population would be unethical. The implementa-
tion of a positive control would have required the standalone 
administration of a positive control (e.g., moxifloxacin) and 
adequate washout prior to starting apalutamide treatment, 
to avoid any carryover effect on the predose (Day − 1) and 
Cycle 1 Day 1 (C1D1) ECG assessments. Moreover, there 
is limited safety experience with apalutamide at a dose of 
> 240 mg from previous clinical studies. Thus, an alterna-
tive multiple dose-dedicated QTc study design was chosen 




Enrolled patients were diagnosed with adenocarcinoma 
of the prostate and with either high-risk nmCRPC [pros-
tate-specific antigen (PSA) doubling time ≤ 10 months] or 
mCRPC. Other inclusion factors were surgical or medi-
cal castration with testosterone levels < 50 ng/dL, East-
ern Cooperative Oncology Group (ECOG) performance 
status 0 or 1, adequate bone marrow and organ function, 
QTcF ≤ 470 ms, and left ventricular ejection fraction of 
> 45%. Key exclusion criteria included known brain metas-
tases, prior treatment with enzalutamide or apalutamide, 
grade ≥ 2 electrolyte abnormalities (hypokalemia, hypocal-
cemia, hypomagnesemia), uncontrolled hypertension, signif-
icant cardiac function abnormalities on screening ECG, and 
history or evidence of certain cardiac conditions. Patients 
requiring concurrent therapy with medications known to be 
associated with QTc interval prolongation and an increased 
risk of torsades de pointes were excluded from the study. Per 
protocol, strong CYP3A4 inducers, strong CYP2C8 induc-
ers (e.g., rifampin), and strong CYP2C8 inhibitors (e.g., 
gemfibrozil) were prohibited to not influence apalutamide 
exposure levels.
Study design
This was an open-label, multicenter, phase Ib study to inves-
tigate the effect of daily apalutamide (240 mg, orally) on 
ventricular repolarization (QTc). Approximately 42 patients 
with high-risk nmCRPC (defined as having a PSA doubling 
time of ≤ 10 months) or mCRPC were planned to be enrolled 
to ensure that at least 38 patients completed the study.
The study consisted of screening, treatment, and follow-
up phases. After providing informed consent, the patients 
entered a 28-day screening phase for determination of eli-
gibility. If eligible, patients began the open-label treatment 
phase and were monitored for PK, pharmacodynamics [(PD) 
ECGs], and safety (including cardiac safety). Apalutamide 
was administered in continuous 28-day treatment cycles. The 
duration of the treatment phase for PD (ECG) and PK data 
collection was from baseline on C1D−1 until C3D1 (Day 
57). Patients were allowed to continue apalutamide treat-
ment after C3D1 until disease progression, withdrawal of 
consent, loss to follow-up, the occurrence of unacceptable 
toxicity, or loss of clinical benefit (investigator opinion). 
The follow-up phase for AEs lasted from discontinuation 
of apalutamide until 30 days after the last dose. Upon dis-
continuation of study drug, patients returned once for an 
end-of-treatment (EoT) visit ≤ 30 days after their last dose.
Pharmacodynamic (ECG) evaluations
Patients were admitted to the study center on C1D−1 (base-
line), C1D1, and C1D3 for PK/PD evaluation. Study drug 
intake was planned at 9:00 a.m. on C1D1 and C1D3 after 
overnight fasting. Continuous 12-lead ECGs were col-
lected by a Holter monitor on C1D−1, C1D1, and C3D1 
from 8:00 a.m. to 3:00 p.m. Triplicate 12-lead ECGs were 
obtained during a 10-min time interval at the following time 
points: at predose (− 0.5 h) and at 1, 2, 3, 4, and 5 h after 
apalutamide administration. This 10-min timeframe began 
5 min before and ended 5 min after each scheduled time 
point. Holter recordings were sent to a blinded, third-party, 
central ECG contract laboratory for 12-lead ECG selec-
tion/extraction, ECG interval measurements, and ECG 
interpretation.
ECG parameters measured included QRS (the onset of 
ventricular depolarization), PR (the period extending from 
the beginning of the onset of atrial depolarization until the 
beginning of the QRS complex), RR (with R being the point 
corresponding to the peak of the QRS complex of the ECG 
wave, and RR being the interval between successive Rs), 
and QT (electrical depolarization and repolarization of the 
ventricles).
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Pharmacokinetic evaluations
After apalutamide administration on C1D1 and C3D1, 
time-matched PK blood samples were collected ≤ 5 min 
after completion of the 10-min timeframe for planned ECG 
collection at predose (− 0.5 h) and at 1, 2, 3, 4, and 5 h 
postdose. To calculate an area under the curve (AUC) value 
over 24 h after the first dose (C1D1), a 24-h PK sample 
was also collected during C1D2. Plasma concentrations 
of apalutamide and N-desmethyl apalutamide were deter-
mined using validated liquid chromatography/tandem mass 
spectrometry methods. The assay consisted of protein pre-
cipitation followed by liquid chromatography with tandem 
mass spectrometric detection. Stable isotope-labeled internal 
standards were used for quantification. Chromatography was 
performed with a Waters Xbridge C18 column (50 × 2.1 mm, 
3.5 µm) using a gradient with 0.1% formic acid and ace-
tonitrile. An API5000 mass spectrometer in the negative 
ion mode with a Turbo-Ionspray Interface (AB SCIEX, 
MA, USA) was used. Multiple reaction monitoring (MRM) 
transitions were from m/z 476.1 to 419.1 and from 479.1 
to 419.1 for apalutamide and the internal standard, respec-
tively. For N-desmethyl apalutamide and the internal stand-
ard, respectively, MRM transitions were from m/z 464.1 to 
235.0 and from 469.2 to 240.1. The quantification range was 
0.0250–25.0 µg/mL for both analytes, and the assay perfor-
mance was monitored using quality control samples. The 
recorded values all met the acceptance criteria.
PK parameters calculated for apalutamide and N-desme-
thyl apalutamide using noncompartmental analysis included 
Cmax, tmax, AUC from time 0 to 24 h after dosing (AUC 24h), 
and the minimum observed plasma concentration (Cmin). 
Additionally, the accumulation index (AI), metabolite:parent 
drug ratio, corrected for molecular weight (MPR; for N-des-
methyl apalutamide only), and peak/trough ratio at steady 
state (PTR) were also calculated.
The PK/PD data collection sought to determine the 
potential relationship between change from baseline in QTc 
(ΔQTc) and the plasma concentrations of apalutamide and 
N-desmethyl apalutamide. The measured QT data were cor-
rected for heart rate using Fridericia (QTcF) [18], Bazett 
(QTcB), and a study-specific correction Power (QTcP) cor-
rection method. The correlation between QTcF and RR was 
not significant, with a slope of 0.031 and a 90% confidence 
interval (CI) (− 0.01 to 0.07) that included zero. A similar 
analysis with the QTcP method also showed no statistically 
significant relationship between QTc and RR, whereas with 
the QTcB method a statistically significant relationship 
between QTc and RR was observed. Overall, these analyses 
support the use of the QTcF method as the primary correc-
tion method; thus, only QTcF data are reported herein. Base-
line was defined as the mean QTc values of the triplicate 
ECG measurements taken at baseline. These baseline QTc 
values were time-matched with those on C1D1 and C3D1. 
The ΔQTc was calculated at each time point. The primary 
endpoint was the maximum mean ΔQTc on C3D1, which 
was estimated by the mean ΔQTc at around tmax (i.e., steady 
state). The duration of PD and PK assessments during the 
treatment phase was from baseline until C3D1.
Safety evaluations
Patients were monitored for safety during the screening, 
treatment, and follow-up phases until 30 days after the last 
dose of study drug. The safety evaluations included AE 
reporting, clinical laboratory safety evaluations, ECGs, 
multigated acquisition scan, or echocardiogram (screening 
only for determination of left ventricular ejection fraction), 
ECOG performance status scores, vital signs, and physical 
examination. For patients who remained in the study after 
three cycles of apalutamide treatment, collection of AEs was 
limited to serious AEs (SAEs) and grade ≥ 3 AEs. Patients 
were followed for disease progression as clinically indicated 
per institutional guidelines, which could include PSA moni-
toring or imaging collected at the discretion of the investiga-
tor. The safety population included all patients who received 
at least one dose of apalutamide.
Statistical analysis
The clinical cutoff for the statistical analysis of the study 
was defined when the last patient enrolled had completed 
the C3D1 (Day 57) assessments. For the statistical analysis 
based on the primary correction method (QTcF), the mean 
changes from baseline (ΔQTcF) at each time point were 
summarized [mean, standard deviation (SD), median and 
range, two-sided 90% CI]. The primary endpoint analysis 
focused on the maximum mean ΔQTcF at C3D1, which was 
estimated by the mean QTcF change at around tmax, the time 
when Cmax was reached. The mean ΔQTcF (± SD) over time 
was plotted. For each treatment and time point of measure-
ment, HR, QRS, PR, and RR intervals, as well as the change 
from baseline in HR, QRS, PR, and RR (ΔHR, ΔQRS, ΔPR, 
ΔRR), were summarized using descriptive statistics (mean, 
SD, median, range, and 90% CI).
Individual plasma concentrations for apalutamide and its 
active metabolite N-desmethyl apalutamide were tabulated 
with descriptive statistics (including arithmetic mean, SD, 
coefficient of variation, median, minimum, and maximum) 
at each sampling time point for each visit. Individual and 
mean plasma concentration–time profiles were plotted.
A linear mixed-effects model was fitted to the ΔQTc 
data from C1D1 and C3D1 with either parent or metabolite 
concentration as a predictor and patient as a random effect. 
On the basis of these relationships, the predicted population 
average ΔQTc and its corresponding upper 90% two-sided 
461Cancer Chemotherapy and Pharmacology (2018) 82:457–468 
1 3
CI bound were computed at the mean Cmax of apalutamide 




At the time of clinical cutoff, 45 men enrolled at five study 
centers received at least one dose of apalutamide and were 
included in the safety analysis set. At study entry, the major-
ity (97.8%) of patients had mCRPC. One patient had high-
risk nmCRPC. Forty three of the 45 patients were consid-
ered study completers (defined as having completed C3D1 
ECG collection and PK sampling procedures in the pres-
ence of adequate compliance with intake of the study drug 
during Cycles 1 and 2) and were included in the primary 
analysis set. Median age at study entry was 67 years (range 
52–86 years) (Table 1). All patients had received therapy 
for prostate cancer prior to study entry in addition to ADT 
or surgical castration; the most commonly prescribed prior 
therapies were bicalutamide (89%), abiraterone acetate 
(42%), and docetaxel (38%) (Table 1). Overall, study partici-
pants were largely compliant with avoidance of prohibited 
medications that could influence apalutamide or N-desme-
thyl apalutamide PK.
Patient disposition
At the time of clinical cutoff, the median treatment dura-
tion was 5 months (range 2–8 months); 82% of patients had 
received treatment for ≥ 3 months. Furthermore, 13 of 45 
patients had discontinued treatment. Treatment was discon-
tinued due to progressive disease in 12 patients, and one 
patient withdrew consent.
Primary endpoint
A total of 831 evaluable ECGs were reviewed in this study, 
out of 855 expected ECG extractions. For each QTc cor-
rection method, the relation between QTc and RR at base-
line was evaluated graphically by plotting the logarithm 
of baseline QTc values against the logarithm of the cor-
responding RR intervals. This analysis supported the QTcF 
method being used as the primary correction method. The 
primary endpoint was maximum mean ΔQTcF on C3D1. 
There was no notable difference in QTcF intervals between 
baseline (Day − 1) and after the first dosing (C1D1). For all 
the corresponding time points on C3D1, there were mean 
increases from baseline in QTcF, but no obvious time-related 
trends over the course of the day. The least squares mean 
increases from baseline on C3D1 ranged from 8.0 to 12.4 ms 
(Table 2). The least squares mean (standard error) QTcF 
change at tmax on C1D1 and on C3D1 was + 1.9 (1.6) ms and 
+ 12.4 (2.1) ms, respectively. The upper limit of the 90% CI 
of the least squares mean baseline corrected QTcF change at 
each postdose time point was below 10 ms for C1D1 (maxi-
mum of upper limits = 4.5 ms) and above 10 ms, for C3D1 
(maximum of upper limits = 16.0 ms).
Patients with QTcF intervals exceeding the thresh-
old values of 450, 480, and 500  ms are summarized 
in Table 3. Twelve patients had QTcF value > 450 and 
≤ 480  ms at baseline while the number increased to 
20 patients on C3D1. One patient had a QTcF interval 
> 480 and ≤ 500 ms at 1 h postdose on C3D1; this same 
patient also had a predose (C1D1, at − 1 h) QTcF value 
of 469.3 ms. No QTcF intervals > 500 ms were recorded. 
Numbers of patients with a QTcF interval change from 
baseline exceeding the threshold values of 30 or 60 ms 
are also summarized in Table 3. Two patients on C1D1 
and nine patients on C3D1 had a QTcF interval change 
from baseline of > 30 but ≤ 60 ms. Among the patients 
with QTcF interval changes from baseline of > 30 ms but 
≤ 60 ms, no association was observed with the presence 
of underlying electrolyte abnormalities or significant car-
diac medical history. One patient had a QTcF interval 
change from baseline of 60.4 ms at 1 h postdose on C3D1 
Table 1  Patient and disease characteristics
ECOG PS Eastern Cooperative Oncology Group performance status
Baseline characteristic Total (N = 45)
Median age, year (range) 67 (52–86)
Race, n (%)
 White 42 (93)
 Black or African American 3 (7)
Median weight, kg (range) 80 (50–135)
Median time from initial diagnosis, mo (range) 68.2 (3.9–280.3)
Extent of disease, n (%)
 Bone 40 (91)





ECOG PS, n (%)
 0 27 (60)
 1 18 (40)
Median testosterone, nM (range) 0.85 (0.07–1.63)
Prior therapy, n (%) 45 (100)
 Bicalutamide 40 (89)
 Abiraterone acetate 19 (42)
 Docetaxel 17 (38)
 Cabazitaxel 11 (24)
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(455.7 ms). The two patients with QTcF > 480 ms or with 
QTcF increase of > 60 ms from baseline did not have a 
significant cardiac medical history and did not use any 
concomitant medications with a liability for QTc prolon-
gation. The patient with QTcF > 480 ms on C3D1 showed 
grade 1 hypocalcemia at baseline and C3D1, but potassium 
and magnesium levels were normal.
Secondary endpoints
For all time points on C1D1, mean heart rate was increased 
from baseline (Table 4), without obvious time-related trends 
over the course of the day. The mean increases from baseline 
on C1D1 ranged from 0.1 to 2.5 bpm. For all time points 
on C3D1, there were mean decreases from baseline in HR, 
but with no obvious time-related trends over the course of 
Table 2  Mean ΔQTcF over time 
after single dose and steady 
state
CI confidence interval, LS least squares, SD standard deviation, SE standard error, C1D−1 Cycle 1 Day 
− 1, C1D1 Cycle 1 Day 1, C3D1 Cycle 3 Day 1
a The time-matched baseline is defined as the mean values of the triplicate electrocardiographic measure-
ments taken on C1D−1, at the time points matching with those on C1D1 and C3D1
b A repeated-measures mixed model was used with time point and baseline value of QTc as fixed effect, and 
patient as a random effect
Absolute QTcF  intervala, ms ΔQTcF (LS mean)  intervalb, ms
N Mean (SD) 95% CI N Mean (SE) 90% CI
C1D1
 Predose 43 428.7 (13.5) (424.5–432.9) 43 − 0.7 (1.59) − 3.4 to 1.9
 1 h 42 430.1 (14.5) (425.6–434.6) 41 − 0.4 (1.62) − 3.1 to 2.3
 2 h 43 432.4 (15.2) (427.7–437.0) 42 1.9 (1.61) − 0.8 to 4.5
 3 h 43 424.7 (13.9) (420.4–429.0) 42 − 3.1 (1.61) − 5.8 to − 0.4
 4 h 43 425.7 (14.5) (421.3–430.2) 42 − 2.1 (1.61) − 4.8 to 0.6
 5 h 43 422.4 (15.9) (417.5–427.3) 41 − 5.5 (1.62) − 8.2 to − 2.8
C3D1
 Predose 42 441.6 (16.8) (436.3–446.8) 42 12.0 (2.14) 8.4–15.5
 1 h 42 442.7 (18.6) (436.9–448.5) 41 12.3 (2.16) 8.7–15.9
 2 h 43 442.9 (16.4) (437.8–447.9) 42 12.4 (2.15) 8.8–16.0
 3 h 42 439.3 (15.7) (434.4–444.2) 41 10.9 (2.15) 7.3–14.5
 4 h 42 436.5 (14.2) (432.0–440.9) 41 8.2 (2.15) 4.6–11.8
 5 h 42 436.0 (16.3) (430.9–441.1) 40 8.0 (2.16) 4.4–11.6
Table 3  Categorical analysis 
of QTcF at baseline and post 
apalutamide treatment
C1D−1 Cycle 1 Day − 1, C1D1 Cycle 1 Day, C3D1 Cycle 3 Day 1
a Percentages are calculated with the number of patients in primary analysis as denominators and only the 
worst value for a patient is presented; the C1D1 predose measurement and C1D−1 measurement are con-
sidered as baseline
b Percentages are calculated with the number of patients in primary analysis as denominators; time-matched 
baseline is defined as the mean values of the triplicate electrocardiographic measurements taken on C1D−1 











Pre- or post-apalutamide QTcF > 450 ms, n (%)a
 > 450 to ≤ 480 ms 12 (28) 6 (14) 20 (47) 20 (47)
 > 480 to ≤ 500 ms 0 0 1 (2) 1 (2)
 > 500 ms 0 0 0 0
QTcF increase from baseline > 30 ms, n (%)b
 > 30 to ≤ 60 ms – 2 (5) 9 (21) 9 (21)
 > 60 ms – 0 1 (2) 1 (2)
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the day. The mean decreases from baseline on C3D1 ranged 
from − 0.4 to − 3.5 bpm. The number of patients with any 
HR [> 100 bpm (n = 3) or < 50 bpm (n = 2)] was similar at 
baseline and on C1D1 and C3D1 (data not shown). Apalu-
tamide did not have a clinically significant effect on HR.
For all time points on C1D1, there were mean decreases 
from baseline in RR interval but with no obvious time-
related trends over the course of the day (Table 4). The 
decreases from baseline on C1D1 ranged from − 6.4 to 
− 21.5 ms. For all time points on C3D1, there were mean 
increases from baseline in RR interval, also with no obvious 
time-related trends over the course of the day. The increases 
from baseline on C3D1 ranged from 6.3 to 41.0 ms. The 
observations on the RR interval are inversely correlated with 
the observations on HR interval.
For mean PR interval over time compared with baseline, 
no obvious time-related trends were noted over the course 
of C1D1 or C3D1 (Table 4). The incidence count and per-
centage of patients with any PR interval > 200 ms by study 
day and by time point was similar at baseline and on C1D1 
or C3D1 (data not shown). No effect of apalutamide on the 
length of the PR interval was apparent. For all time points 
on C1D1 and C3D1, mean increases were observed from 
baseline in the QRS interval (Table 4). The mean increases 
from baseline on C1D1 ranged from 0.5 to 0.9 ms and on 
C3D1 from 1.6 to 2.4 ms. No patients had a QRS interval 
> 110 ms at baseline or on C1D1. QRS intervals > 110 ms 
but ≤ 115 ms on C3D1 were recorded in three patients. The 
largest mean change (increase) in QRS duration from base-
line was 2.4 ms on C3D1 at predose. Overall, no clinically 
relevant effects of apalutamide on the QRS interval were 
observed.
T-wave morphology was monitored, and the number of 
patients with flat, inverted, or biphasic T-waves was similar 
on pretreatment and post-treatment days. For most patients 
Table 4  Change from baseline in heart rate, RR interval, PR interval, 
and QRS interval at C1D1 and C3D1
N Mean ± SD 90% CI
Heart rate, bpm
 C1D1
  Predose 43 0.6 ± 5.83 − 0.9 to 2.1
  1 h 41 0.7 ± 5.96 − 0.9 to 2.3
  2 h 42 2.4 ± 13.11 − 1.0 to 5.8
  3 h 42 2.5 ± 11.97 − 0.6 to 5.7
  4 h 42 0.1 ± 13.26 − 3.4 to 3.5
  5 h 41 2.2 ± 6.01 0.6 to 3.8
 C3D1
  Predose 42 − 2.5 ± 6.09 − 4.0 to − 0.9
  1 h 41 − 1.7 ± 5.93 − 3.2 to − 0.1
  2 h 42 − 3.4 ± 6.60 − 5.1 to − 1.7
  3 h 41 − 1.3 ± 13.69 − 4.9 to 2.3
  4 h 41 − 3.5 ± 14.82 − 7.4 to 0.4
  5 h 40 − 0.4 ± 7.17 − 2.3 to 1.5
RR interval, ms
 C1D1
  Predose 43 − 7.5 ± 89.97 − 30.6 to 15.5
  1 h 41 − 13.3 ± 92.29 − 37.6 to 11.0
  2 h 42 − 16.1 ± 92.55 − 40.1 to 8.0
  3 h 42 − 16.0 ± 83.55 − 37.7 to 5.7
  4 h 42 − 6.4 ± 86.57 − 28.9 to 16.1
  5 h 41 − 21.5 ± 63.13 − 38.1 to 4.9
 C3D1
  Predose 42 39.0 ± 89.10 15.8 to 62.1
  1 h 41 27.5 ± 84.93 5.2 to 49.9
  2 h 42 41.0 ± 77.88 20.8 to 61.2
  3 h 41 33.2 ± 143.13 − 4.5 to 70.8
  4 h 41 36.4 ± 141.19 − 0.7 to 73.5
  5 h 40 6.3 ± 79.87 − 15.0 to 27.6
PR interval, ms
 C1D1
  Predose 43 2.6 ± 12.34 − 0.5 to 5.8
  1 h 41 1.9 ± 13.01 − 1.6 to 5.3
  2 h 41 − 0.7 ± 10.12 − 3.4 to 2.0
  3 h 41 − 1.1 ± 9.78 − 3.7 to 1.5
  4 h 41 − 1.8 ± 9.51 − 4.3 to 0.7
  5 h 41 − 0.3 ± 6.31 − 2.0 to 1.4
 C3D1
  Predose 42 2.2 ± 13.70 − 1.3 to 5.8
  1 h 41 0.1 ± 17.29 − 4.4 to 4.7
  2 h 42 1.6 ± 11.38 − 1.4 to 4.5
  3 h 40 − 0.9 ± 15.72 − 5.1 to 3.3
  4 h 40 − 2.7 ± 14.82 − 6.6 to 1.3
  5 h 40 0.6 ± 8.54 − 1.7 to 2.8
QRS interval, ms
 C1D1
  Predose 43 0.5 ± 3.36 − 0.4 to 1.4
  1 h 41 0.9 ± 3.35 0.0 to 1.8
Table 4  (continued)
N Mean ± SD 90% CI
  2 h 42 0.5 ± 3.97 − 0.5 to 1.6
  3 h 42 0.8 ± 3.58 − 0.2 to 1.7
  4 h 42 0.9 ± 3.00 0.1 to 1.6
  5 h 41 0.5 ± 3.53 − 0.4 to 1.5
 C3D1
  Predose 42 2.4 ± 4.53 1.2–3.6
  1 h 41 1.6 ± 5.05 0.3–2.9
  2 h 42 1.9 ± 4.91 0.7–3.2
  3 h 41 2.2 ± 4.88 0.9–3.4
  4 h 41 1.6 ± 5.07 0.3–3.0
  5 h 40 2.3 ± 4.71 1.1–3.6
SD standard deviation, CI confidence interval, C1D−1 Cycle 1 
Day − 1, C1D1 Cycle 1 Day 1, C3D1 Cycle 3 Day 1
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with T-wave abnormalities observed during the treatment 
phase, these observations were also noted on predose ECG 
before apalutamide administration. De novo T-wave abnor-
malities were observed in three patients (7%), which were 
absent at baseline, and no QTcF prolongation ≥ 480 ms was 
observed in these three patients. Apalutamide treatment did 
not have an apparent association with the appearance or 
worsening of T-wave abnormalities, and no U-waves were 
observed in any patient.
Mean plasma concentrations over time for apalutamide and 
N-desmethyl apalutamide are shown in Fig. 1a, b. Repeated 
once-daily administration of 240-mg apalutamide under fasted 
conditions resulted in a three- and fivefold increase of Cmax 
and AUC 24h, respectively, when comparing apalutamide sys-
temic exposure between C1D1 and C3D1 (Table 5). Median 
tmax was reached at approximately 2 h post dose on C1D1 
and C3D1. At steady state (C3D1), the active metabolite 
N-desmethyl apalutamide exhibited a flat PK profile with a 
mean PTR of 127%. The MPRs for Cmax and AUC 24h were 
105 ± 21 and 133 ± 28%, respectively (Table 5). A significant 
correlation was observed between the change in QTcF from 
baseline and the concentration of apalutamide (slope estimate, 
2.89; 90% CI, 2.11–3.67; p < 0.0001) (Fig. 1c). The predicted 
ΔQTcF (90% CI) at a mean Cmax of 5.95 µg/mL was 13.8 ms 
(9.77–17.85). Likewise, a significant correlation was observed 
between the change in QTcF from baseline and the concentra-
tion of N-desmethyl apalutamide (slope estimate, 2.28; 90% 
CI 1.70–2.85; p < 0.0001) (Fig. 1d). For instance, on C3D1 
the predicted ΔQTcF (90% CI) at a mean steady state Cmax of 
5.84 µg/mL was 12.0 ms (8.58–15.38).
Safety
Dose modifications were allowed for toxicity attributed to 
apalutamide, and re-escalation was permitted if first dis-
cussed with and approved by the sponsor. The majority of 
patients had neither dose reduction (42 patients, 93%) nor 








Fig. 1  Plasma concentration of apalutamide and N-desmethyl apalu-
tamide and their association with QTcF: a mean plasma concentra-
tion–time profiles of apalutamide after administration of 240  mg 
apalutamide on C1D1 and C3D1; b mean plasma concentration–time 
profiles of N-desmethyl apalutamide after administration of 240 mg 
apalutamide on C1D1 and C3D1; c scatter plot of the relationship 
between ΔQTcF and plasma concentration of apalutamide; d scatter 
plot of the relationship between ΔQTcF and plasma concentration of 
N-desmethyl apalutamide
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re-escalations after initial dose reduction. Drug-related tox-
icities leading to temporary dose interruption included grade 
3 diarrhea and aspartate transaminase/alanine transaminase 
increase and grade 2 fatigue. Two patients required a dose 
reduction due to fatigue. Thirteen (29%) patients discontin-
ued treatment, with 12 of those discontinuing due to pro-
gressive disease and one due to withdrawal of consent (no 
discontinuations were due to AEs).
Thirty-seven (82%) patients experienced at least one 
treatment-emergent AE (TEAE), most of which were 
grades 1–2. The most commonly reported TEAEs (≥ 10% 
of patients) were fatigue (40%), decreased appetite (24%), 
back pain (16%), diarrhea and dyspnea (13% each), rash/
erythema (13%), and constipation and nausea (11% each). 
No treatment-emergent seizures were reported. The AEs 
recorded in this study were consistent with those observed 
in other published apalutamide studies [6, 7, 19, 20]. Grade 
3 TEAEs were reported in eight (18%) patients and grade 
4 AEs in two (4%) patients. Grade 3 TEAEs reported in 
> 1 patient were anemia (3 patients, 7%) and back pain (2 
patients, 4%); these grade 3 TEAEs were not considered 
related to apalutamide treatment. Three patients reported 
grade 3 toxicities considered possibly or probably related 
to apalutamide, including fatigue, diarrhea, and aspartate 
transaminase/alanine transaminase increase. In one patient, 
grade 3 cardiac failure was reported on study Day 45 and 
was not considered related to apalutamide treatment. Grade 
3 nervous system disorder and spinal cord compression 
were reported in two patients, were not considered related 
to apalutamide treatment, and occurred in an overall con-
text of worsening vertebral metastatic disease. One patient 
experienced grade 4 thrombocytopenia, which was not con-
sidered related to apalutamide treatment and occurred in the 
context of progressive disease. Another patient had grade 4 
neutropenia not considered related to apalutamide treatment 
that occurred while the patient took sulfamethoxazole plus 
trimethoprim for a bladder infection.
Five patients experienced ≥ 1 SAE, but none were con-
sidered related to apalutamide treatment; SAEs were grades 
1–3, except for a grade 4 SAE of general health deteriora-
tion in one patient, who subsequently died from progres-
sive disease. One patient experienced a grade 3 SAE of 
medullary compression, which was considered not related 
to apalutamide treatment and likely related to underlying 
metastatic disease in the vertebra. Another patient with bone 
metastases experienced a grade 3 SAE of progressive lower 
back pain, which was attributed to the magnetic resonance 
imaging-verified metastatic disease in the pelvis. One patient 
experienced multiple SAEs: grade 2 hypercalcemia, grade 
3 jaw necrosis, grade 3 pain left hip, and grade 3 neurologic 
deficit due to spinal cord compression resulting from bone 
metastases; none were considered related to apalutamide 
treatment. The final patient, a 70-year-old man with a his-
tory of hypertension, mitral valve prolapse, and type 2 dia-
betes, experienced multiple SAEs, including grade 3 lower 
back pain, grade 2 infection, and grade 2 delirium, none 
of which were considered related to apalutamide treatment. 
This patient also experienced a grade 3 SAE of heart failure 
caused by de novo atrial fibrillation that was not considered 
related to apalutamide treatment.
Laboratory values were collected over time (data not 
shown). Most patients had occasional changes in serum 
chemistry and some hematologic abnormalities, the major-
ity of which were grade 0–2 in severity. Elevated thyroid-
stimulating hormone (TSH) levels above the upper limit of 
normal during the study were observed in 13 patients (29%), 
Table 5  Pharmacokinetics of 
apalutamide and N-desmethyl 
apalutamide
C1D1 Cycle 1 Day 1, C3D1 Cycle 3 Day 1, Cmax maximum observed plasma concentration, tmax time to 
Cmax, AUC 24h AUC from time 0 to 24 h after dosing, Cmin minimum observed plasma concentration, PTR 
peak/trough ratio at steady state, AI accumulation index, MPR metabolite:parent drug ratio corrected for 
molecular weight
a All values are presented as the mean (SD) except for tmax, which is presented as the median (range), or as 
otherwise noted
Parametera Apalutamide N-desmethyl apalutamide
C1D1 (N = 45) C3D1 (N = 43) C1D1 (N = 45) C3D1 (N = 43)
Cmax, µg/mL 2.06 (0.58) 5.95 (1.66) 0.092 (0.057) 5.85 (1.04)
tmax, h 2.12 (1.08–5.10) 2.10 (1.00–4.17) 24.00 (4.10–24.58) 1.10 (0.00–4.17)
AUC 24h, µg·h/mL 21.1 (4.93) 100 (31.6) 1.41 (0.79) 124 (23.0)
Cmin, µg/mL – 3.72 (1.19) – 4.66 (0.90)
PTR, % – 163 (24.7) – 127 (13.3)
AI(Cmax) – 3.09 (1.26) – 82.1 (50.5)
AI(AUC24h) – 4.95 (1.69) – 122 (108)
MPR Cmax, % (SD) – – – 105 (20.8)
MPR AUC 24h, % (SD) – – – 133 (28.0)
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were usually limited in magnitude and, in the majority of 
cases, thyroid hormone levels stayed within normal limits. In 
two patients (4%), significant TSH elevations were observed 
in combination with a decrease in thyroid hormone levels. 
One of these two patients had a medical history of hypothy-
roidism and required an increase in thyroid supplementation 
therapy in the course of the study.
Discussion
These data from an open-label, multicenter, phase Ib dedi-
cated QT/QTc study that investigated the effect of apaluta-
mide on ventricular repolarization and other ECG param-
eters confirm the absence of major effects from apalutamide 
on the QTc interval in men with CRPC. This modified QTc 
study, tailored to the oncologic setting and taking into 
account the PK characteristics of apalutamide, was rigor-
ously executed with time-matched ECG and PK sample 
collection and central blinded ECG interval measurement 
and interpretation. Across all time points at steady state, 
the baseline-adjusted QTc intervals and the upper bounds 
of their associated 90% CIs were ≤ 20 ms following 240-
mg once-daily doses of apalutamide. Consistent with the 
primary endpoint results, categorical analysis of absolute 
QTcF values revealed a slightly higher incidence of QTcF 
readings > 450 but ≤ 480 ms on C3D1 compared with base-
line and C1D1. These results indicate that the QTc increases 
observed with apalutamide become apparent at steady state 
(after minimally 4 weeks) but not after the first dose, likely 
because of an accumulation of apalutamide with repeat 
dosing.
There were two outliers with a larger QTc prolonga-
tion. One patient with a QTcF interval > 480 and ≤ 500 ms 
also had a higher predose QTcF value (469.3 ms) and had 
a concurrent C3D1 observation of grade 1 hypocalcemia. 
A second patient had a large absolute ΔQTcF (60.4 ms) at 
1 h post dose on C3D1 (QTcF 455.7 ms), which may have 
been related to exposure to apalutamide (6.84 µg/mL) or 
N-desmethyl apalutamide (8.21 µg/mL). However, the QTcF 
value was lower at 2 h post dose despite higher drug concen-
trations [QTcF of 446 ms (change of 58.3 ms)], with expo-
sure of apalutamide and N-desmethyl apalutamide of 8.77 
and 8.87 µ/mL, respectively, suggesting that the increase of 
more than 60.4 ms was not consistent at similar exposure 
within the same individual. No patients discontinued treat-
ment due to QTc prolongation, and no evidence of develop-
ment of ventricular arrhythmias was observed that could be 
attributed to underlying QTc prolongation.
According to Sarapa et al., the magnitude of changes 
in QTcF interval (as observed in the present study) may 
be considered a mild to moderate QTc-prolonging effect 
for an anticancer agent, and these same authors have 
suggested that a dedicated QTc study for anticancer agents 
that excludes ∆QTc of < 20 ms can be concluded as a neg-
ative study [21], consistent with the present data showing 
no new clinical concerns [4]. Our data are supported by a 
small and voluntary QTc substudy of the SPARTAN trial 
[6], which also revealed no patients in the apalutamide 
arm with a QTcF interval > 480 ms. In the placebo arm of 
the SPARTAN study, two of six patients had at least one 
postdose QTcF interval > 450 and ≤ 480 ms; one of these 
two patients had a baseline QTcF interval > 450 ms.
De novo T-wave abnormalities were observed in 
three patients (7%) and were absent at baseline, and no 
QTcF prolongation ≥ 480 ms was observed in these three 
patients. No evidence for an apalutamide treatment effect 
was noted on the length of the PR interval in our study. 
The observed mean increases in QRS duration as observed 
on C3D1 were minimal (< 2.5 ms) and are considered not 
clinically meaningful.
Overall, exposures of apalutamide and its extent of 
accumulation observed in this study are consistent with 
those previously reported [7]. To explore the relation-
ship between apalutamide concentration at steady state 
and QTcF, PK (plasma concentration) and PD (change 
from baseline in QTcF) data were analyzed using a linear 
mixed-effects model. The analysis revealed an association 
between plasma concentration of apalutamide and QTcF 
and predicted a prolongation of 13.81 ms at Cmax at steady 
state (C3D1), with an upper bound of two-sided 90% CI 
of 17.85 ms. Because of the correlation between apaluta-
mide and N-desmethyl apalutamide exposures, a similar 
association between plasma concentration of N-desmethyl 
apalutamide and QTcF was detected. Based on the flat 
PK profile of N-desmethyl apalutamide at steady state, 
the apparent association between N-desmethyl apaluta-
mide concentration and QTcF at steady state is consid-
ered less clinically meaningful compared with the parent 
drug. Overall, results of the PK/PD analysis indicated that 
a large effect on ∆QTcF is not expected at steady state fol-
lowing 240 mg daily dose of apalutamide.
These data from a Phase Ib QT/QTc study that investi-
gated the effect of apalutamide on QTc intervals revealed no 
new safety signals associated with apalutamide treatment in 
men with CRPC. For the primary endpoint, no significant 
safety findings related to QT prolongation were documented 
and there were no observed arrhythmias related to apaluta-
mide. Overall, the safety profile observed in this study was 
as expected based on the known safety profile of apaluta-
mide and results from other studies [6, 7, 19, 20].
Overall, these data demonstrate that apalutamide does 
not produce clinically meaningful changes in QTc interval 
or produce a concerning effect on ventricular repolarization 
in patients with CRPC.
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